Statements (45)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
amphetamine
|
| gptkbp:age |
adolescents
adults children |
| gptkbp:approvalYear |
2016
|
| gptkbp:broadcastOn |
gptkb:Schedule_II_controlled_substance
|
| gptkbp:contraindication |
hyperthyroidism
advanced arteriosclerosis known hypersensitivity to amphetamine products moderate to severe hypertension symptomatic cardiovascular disease |
| gptkbp:countryOfOperation |
gptkb:United_States
|
| gptkbp:form |
orally disintegrating tablet
12.5 mg 15.7 mg 18.8 mg 21.9 mg 3.1 mg 6.3 mg 9.4 mg |
| gptkbp:genericAvailable |
no
|
| https://www.w3.org/2000/01/rdf-schema#label |
Adzenys XR-ODT
|
| gptkbp:indication |
gptkb:attention_deficit_hyperactivity_disorder
|
| gptkbp:manufacturer |
gptkb:Neos_Therapeutics
|
| gptkbp:mechanismOfAction |
stimulant
|
| gptkbp:NDCCode |
57962-0303-30
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:releaseYear |
extended-release
|
| gptkbp:riskFactor |
sudden cardiac death
potential for abuse dependence psychiatric adverse events |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
anxiety
weight loss insomnia dry mouth irritability decreased appetite increased blood pressure |
| gptkbp:storage |
store at 20°C to 25°C (68°F to 77°F)
|
| gptkbp:bfsParent |
gptkb:Amphetamine
gptkb:amphetamine |
| gptkbp:bfsLayer |
6
|